Current Leading Therapies for Multiple Myeloma
Nina Shah, MD, discusses the potential therapies that could emerge in 2022 for multiple myeloma.
Nina Shah, MD: Today as we go from 2021 to 2022, I would say the leading therapies for induction therapy for transplant-eligible patients are RVd [lenalidomide (Revlimid), bortezomib (Velcade), and dexamethasone] or daratumumab [Darzalex]–RVd based on the GRIFFIN trial [NCT02874742]. That’s becoming a newer and more used regimen, [although] KRd [carfilzomib (Kyprolis), lenalidomide, and dexamethasone] is still a potential for that. I do think transplant still has a role. This has been supported by the IFM trial [NCT01191060] and more recently, by the FORTE trial [NCT02203643]. For maintenance therapy. The jury’s still out. Lenalidomide does give overall survival advantage but perhaps giving carfilzomib in combination with lenalidomide gives you a longer PFS [progression-free survival] as per the FORTE trial and may be particularly better for high-risk patients.
In the relapsed or refractory setting, [specifically] in the early relapse setting, daratumumab in combination with carfilzomib or isatuximab [Sarclisa] in combination with carfilzomib is a very effective treatment and should be considered in the second line. You can also consider things like daratumumab, pomalidomide [Pomalyst], and dexamethasone. In the late line, we are on the horizon to now embrace the BCMA [B-cell maturation antigen] therapies. Hopefully we’re going to have another CAR T-cell therapy available as well as, in the near future, bispecific T-cell engagers.
Fostering Academic, Community Practice Collaboration for Bispecific Therapy in Multiple Myeloma
December 26th 2024Experts in multiple myeloma spoke about optimal treatment strategies for patients who receive bispecific therapy, focusing specifically on facilitating a multifaceted approach between academic and community practices.
